538 related articles for article (PubMed ID: 31755336)
21. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
[TBL] [Abstract][Full Text] [Related]
22. Identification of Novel EGFR Inhibitors for the Targeted Therapy of Colorectal Cancer Using Pharmacophore Modelling, Docking, Molecular Dynamic Simulation and Biological Activity Prediction.
Krishnan K A; Valavi SG; Joy A
Anticancer Agents Med Chem; 2024; 24(4):263-279. PubMed ID: 38173208
[TBL] [Abstract][Full Text] [Related]
23. Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of
Ejaz SA; Aziz M; Fawzy Ramadan M; Fayyaz A; Bilal MS
Molecules; 2023 May; 28(10):. PubMed ID: 37241785
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
25. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
26. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
27. A combination of 2D similarity search, pharmacophore, and molecular docking techniques for the identification of vascular endothelial growth factor receptor-2 inhibitors.
Ai G; Tian C; Deng D; Fida G; Chen H; Ma Y; Ding L; Gu Y
Anticancer Drugs; 2015 Apr; 26(4):399-409. PubMed ID: 25569705
[TBL] [Abstract][Full Text] [Related]
28. Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation.
Wang Y; Peng C; Wang G; Xu Z; Luo Y; Wang J; Zhu W
Chem Biol Drug Des; 2019 May; 93(5):934-948. PubMed ID: 30689282
[TBL] [Abstract][Full Text] [Related]
29. Identification and characterization of agnuside, a natural proangiogenic small molecule.
Pillarisetti P; Myers KA
Eur J Med Chem; 2018 Dec; 160():193-206. PubMed ID: 30340142
[TBL] [Abstract][Full Text] [Related]
30. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
31. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.
Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S
J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122
[TBL] [Abstract][Full Text] [Related]
32. Virtual screening and synthesis of new chemical scaffolds as VEGFR-2 kinase inhibitors.
Elsayed MS; El-Araby ME; Serya RT; Abouzid KA
Arzneimittelforschung; 2012 Dec; 62(12):554-60. PubMed ID: 23023518
[TBL] [Abstract][Full Text] [Related]
33. CHK1 kinase inhibition: identification of allosteric hits using MD simulations, pharmacophore modeling, docking and MM-PBSA calculations.
Al-Shar'i N; Musleh SS
Mol Divers; 2022 Apr; 26(2):903-921. PubMed ID: 33686514
[TBL] [Abstract][Full Text] [Related]
34. Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening.
Li C; Zhang X; Zhang N; Zhou Y; Sun G; Zhao L; Zhong R
Molecules; 2020 Jan; 25(1):. PubMed ID: 31935979
[TBL] [Abstract][Full Text] [Related]
35. An integrated virtual screening approach for VEGFR-2 inhibitors.
Zhang Y; Yang S; Jiao Y; Liu H; Yuan H; Lu S; Ran T; Yao S; Ke Z; Xu J; Xiong X; Chen Y; Lu T
J Chem Inf Model; 2013 Dec; 53(12):3163-77. PubMed ID: 24266594
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel discoidin domain receptor 1 (DDR1) inhibitors using E-pharmacophore modeling, structure-based virtual screening, molecular dynamics simulation and MM-GBSA approaches.
Nada H; Lee K; Gotina L; Pae AN; Elkamhawy A
Comput Biol Med; 2022 Mar; 142():105217. PubMed ID: 35032738
[TBL] [Abstract][Full Text] [Related]
37. Virtual Screening Using Pharmacophore Models Retrieved from Molecular Dynamic Simulations.
Polishchuk P; Kutlushina A; Bashirova D; Mokshyna O; Madzhidov T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757043
[TBL] [Abstract][Full Text] [Related]
38. Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors.
Poonia P; Sharma M; Jha P; Chopra M
Mol Divers; 2023 Oct; 27(5):2053-2071. PubMed ID: 36214962
[TBL] [Abstract][Full Text] [Related]
39. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
[TBL] [Abstract][Full Text] [Related]
40. Computational insights into allosteric inhibition of focal adhesion kinase: A combined pharmacophore modeling and molecular dynamics approach.
Kumar V; Singh P; Parate S; Singh R; Ro HS; Song KS; Lee KW; Park YM
J Mol Graph Model; 2024 Jul; 130():108789. PubMed ID: 38718434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
